AIDS 2010
AIDS 2010: Boosted Darunavir (Prezista) Monotherapy Provides Durable Viral Suppression for Most HIV Patients
- Details
- Category: HIV Treatment
- Published on Tuesday, 17 August 2010 13:56
- Written by Liz Highleyman
More than 90% of patients who switched from a suppressive combination antiretroviral therapy (ART) regimen to ritonavir-boosted darunavir (Prezista) without nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) had undetectable viral load at 96 weeks, according to long-term data from the MONET study presented at the XVIII International AIDS Conference (AIDS 2010) last month in Vienna. Taking into account participants who experienced 2 viral "blips" or made a change from their randomized regimen, however, darunavir/ritonavir monotherapy was not quite as effective as 3-drug combination therapy.
AIDS 2010: Nutritional Supplements May Slow HIV Disease Progression, Boost Immune Recovery, and Lessen Mitochondrial Toxicity
- Details
- Category: HIV Treatment
- Published on Friday, 13 August 2010 13:56
- Written by Liz Highleyman
People with HIV in Botswana who used a multi-vitamin supplement experienced slower disease progression and CD4 T-cell loss, according to a study presented at the XVIII International AIDS Conference (AIDS 2010) last month in Vienna. Two smaller U.S. studies found that zinc supplements were associated with lower likelihood of immune cell decline, while antioxidants helped prevent mitochondrial damage.
AIDS 2010: HIV/HCV Coinfected People with Normal Liver Enzymes Respond Well to Interferon-based Therapy
- Details
- Category: HIV/HCV Coinfection
- Published on Tuesday, 10 August 2010 12:56
- Written by Liz Highleyman
HIV positive people with normal levels of the liver enzyme alanine aminotransferase (ALT) who received hepatitis C therapy using pegylated interferon plus ribavirin responded as well as individuals with elevated ALT, according to findings presented at the XVIII International AIDS Conference (AIDS 2010) last month in Vienna.
AIDS 2010: Drug Resistance Linked to Faster Hepatitis B Liver Disease Progression in HIV/HBV Coinfected Patients
- Details
- Category: HIV/HBV Coinfection
- Published on Tuesday, 10 August 2010 13:56
- Written by Liz Highleyman
HIV/HBV coinfected individuals may be less likely to have hepatitis B virus (HBV) with mutations conferring resistance to lamivudine (3TC; Epivir), but those who do have drug resistance experience faster liver disease progression and are more likely to develop cirrhosis, according to a study from Romania presented last month at the XVIII International AIDS Conference (AIDS 2010) in Vienna.
AIDS 2010: CHARTER Study Finds Neurocognitive Impairment Still Common in ART Era, Linked to Lowest CD4 Cell Count
- Details
- Category: Neurocognitive Problems
- Published on Friday, 06 August 2010 13:56
- Written by Liz Highleyman
Neurocognitive impairment ranging from subtle to severe remains common among people with HIV despite widespread use of effective combination antiretroviral therapy (ART), according to findings from the large CHARTER study presented at the XVIII International AIDS Conference (AIDS 2010) last month in Vienna. Impairment was associated with nadir or lowest-ever CD4 cell count, even among individuals whose immune function has since recovered on ART.
More Articles...
- Half of Children Born to HIV Positive Mothers Do Not Receive Preventive Antiretroviral Drugs
- AIDS 2010: Investigational HIV Drug TBR-652 Reduces Viral Replication and May Dampen Inflammation
- AIDS 2010: Switching from Boosted Protease Inhibitor to Raltegravir Maintains Viral Suppression in Absence of NRTI Resistance
- AIDS 2010: Majority of HIV Positive People on Antiretroviral Therapy May Have Reduced Bone Density
Web Design and Development by